Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

VistaGen Therapeutics, Inc.

  • Shawn Singh, VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety, and other CNS diseases and disorders with high unmet need. Lead candidate, AV-101, is currently in Phase 2 for the treatment of major depressive disorder. PH94B and PH10 are being prepared for Phase 3 for the treatment of social anxiety disorder and MDD, respectively.

  • Date:Monday, February 11
  • Time:1:45 PM - 2:00 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23302
  • Goal for Presentation:Networking
  • Company Website:www.vistagen.com
  • Company HQ City:South San Francisco
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:VTGN
  • Exchange:NasdaqCM
  • CEO/Top Company Official:Shawn K. Singh
  • Year Founded:1998
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:AV-101
  • Development Phase of Primary Product:Phase II
Speakers
Shawn Singh
VistaGen Therapeutics, Inc.
Back